Navigation Links
bioTheranostics' Breast Cancer Index(SM) Predicts Risk for Late Recurrence in Early Stage ER-Positive Breast Cancer Patients
Date:12/10/2010

SAN DIEGO, Dec. 10, 2010 /PRNewswire/ -- bioTheranostics, a bioMerieux company that develops innovative oncology diagnostic tests to support targeted disease management, announced today new findings from a clinical study evaluating the company's Breast Cancer Index (BCI) molecular oncology test. Data from the study were presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

The company also announced that the Breast Cancer Index is now available to provide quantitative assessment of the risk of distant disease recurrence.  The BCI risk assessment  is based on data from a recently completed large, randomized, retrospective trial.(1)

"The results presented in San Antonio today become part of a substantial and growing body of data supporting the clinical value of the Breast Cancer Index," said Richard Ding, chief executive officer of bioTheranostics. "We are pleased to make this valuable test available to oncologists and pathologists in an enhanced format with clinical data specific for late breast cancer recurrence."

The Breast Cancer Index is a combination of HOXB13:IL17BR (H/I) and Molecular Grade Index (MGI), biomarkers that improve risk stratification in patients with estrogen receptor (ER)-positive, lymph-node negative breast cancer. This population represents the majority of breast cancers diagnosed each year.

Data presented today are from the MA.17 study, a previously conducted, randomized prospective trial.  This study evaluated the role of adjuvant endocrine therapy with letrozole in reducing the risk of recurrence and improving disease-free survival among women with breast cancer who completed five years of tamoxifen therapy. As part of the study, Massachusetts General Hospital researchers Paul Goss, MD, PhD and Dennis Sgroi, MD retrospectively evaluated the ability of the Breast Cancer Index to distinguish those patients at risk of late recurrence and those who
'/>"/>

SOURCE bioTheranostics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AltheaDx and Compendia Bioscience Launch the Breast Cancer Segregation Panel™
2. Combined Sales of Seven Emerging Therapies for Breast Cancer, Including Drugs From Sanofi-Aventis and AstraZeneca, Will Total Nearly $5 Billion by 2019
3. Reportlinker Adds Breast Cancer Drug Futures
4. LCS Constructors, Inc. Supports the Cure and Breast Cancer Awareness Month
5. Leading Journal Turns Up the Heat on Cutting-Edge Breast Cancer Treatment
6. K-State Research Team Investigates Mutated Genes Role in Breast Cancer
7. Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting
8. Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting
9. Huiheng Medical, Inc. Announces Agreement to Acquire the ClearPath (TM) Breast Brachytherapy System
10. Abviva Details Patent Information for its Breast Cancer Risk Assessment Technology
11. Abviva Announces Further Patent Issuance for Technology Used in Breast Cancer Diagnostics and Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... BARCELONA, Spain , April 27, 2015  Together ... during the 3rd ESTRO Forum in Barcelona ... Hope, a nonprofit organization with the mission to improve ... Radiating Hope believes that no patient should ... is not affordable. Consequently, it cooperates with hospitals and ...
(Date:4/24/2015)... Leading Regenerative Veterinary Medicine company ... stem-cell product development program and changes its’ name ... strategic direction. , “I am extremely pleased to ... development program has been kicked into high gear ... and hiring of our new Director of Research ...
(Date:4/24/2015)... April 24, 2015  Navitas Life Sciences is delighted to ... of Clinical and Regulatory Services. Shalabh is a proven leader ... and CEO of Kinapse, as well as a Strategy consultant ... Logo - http://photos.prnewswire.com/prnh/20150423/201261LOGO ... commented "I am delighted to welcome Shalabh into this critical ...
(Date:4/23/2015)... (PRWEB) April 23, 2015 The ... intends to conduct a groundbreaking pilot study to ... be reversed in as little as three to ... of metabolic and nutritional medicine—will aggressively target and ... and destroy our aging brain. These include oxidative ...
Breaking Biology Technology:Elekta helps raise $33,000 to bring radiation treatment to developing countries 2Elekta helps raise $33,000 to bring radiation treatment to developing countries 3Vet-Stem, Inc. Meets New Milestones and Changes Name to VetStem Biopharma 2Shalabh Kumar Joins Navitas Life Sciences to Lead their Clinical and Regulatory Services Teams 2New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3
... workforce reduction, NEW YORK, April 4, 2008 ... that it is implementing a,strategic restructuring plan to ... efforts. The plan, which was prompted by the ... clinical trial of Sulonex(TM),(sulodexide) for the treatment of ...
... Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ANP), a ... that the first New Zealand patient,was treated with ... December 2007. A second patient was treated in ... drug-eluting stent for peripheral,arterial disease (PAD) and was ...
... held at the Society for Biomolecular Sciences 14th ... ... Ltd., an,international provider of microfluidic systems in the emerging field of,nano-lifesciences, ... enables researchers to execute physiologically,relevant flow experiments evaluating the adhesion of ...
Cached Biology Technology:Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan 2Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan 3Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan 4Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand 2Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand 3Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand 4Cellix Ltd. Launches VenaEC Biochip for Flow-based Cell-adhesion Assays 2
(Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
(Date:3/26/2015)... 26, 2015 The Granite Club, ... and athletic club, today announced it has implemented a ... of movement for members and staff, while restricting access ... process, we selected FST,s IMID Access system because it ... our members and staff, in addition to unparalleled security," ...
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... to determine if patients with type 2 diabetes can ... cell infusions (ASC) and hyperbaric (above the normal air ... ASC has found "significant benefits" in terms of "improvements ... combination therapy could decrease type 2 diabetes morbidity and ...
... New software developed with help from the Wildlife Conservation ... animals by creating a three-dimensional model using photos taken ... issue of the journal Biology Letters , may ... skins. The new software, developed by Conservation Research Ltd., ...
... Researchers have taken a first look at the broad ... Although scientists have known for more than a ... animals are likely to suffer from low reproductive success, ... is still the subject of debate. The new ...
Cached Biology News:Stem cell infusion and hyperbaric oxygen treatment improve islet function in diabetes 2Tracking tigers in 3-D 2Researchers take first look at the genetic dynamics of inbreeding depression 2Researchers take first look at the genetic dynamics of inbreeding depression 3
Wellpro 96 an automated liquid handling system for 96-well plates that quickly and accurately prepares large quantities of serial dilutions. The Wellpro also performs plate to plate transfers using ...
... Once a macromolecular structure has been determined, ... to a widely diverse audience of scientists, ... printed literature and dissemination over the Internet, ... personal web pages. Printed literature has the ...
ma. plate stack height 70mm...
Buckets for tube holder inserts...
Biology Products: